Truist on Sage Therapeutics (SAGE): 'we remain on the sidelines as we see further pipeline setbacks'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Hold rating and $22.00 price target on Sage Therapeutics (NASDAQ: SAGE)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
